联合应用锂剂和神经阻滞剂治疗时神经阻滞剂恶性综合征的发生风险增加。
Increased risk of occurrence of neuroleptic malignant syndrome on combined treatment with lithium and neuroleptic.
机构信息
P. JOHN ALEXANDER, M.D., Associate Professor, Department of Psychiatry, Kasturba Medical College, Manipal 576 119, Karnataka.
出版信息
Indian J Psychiatry. 1997 Jul;39(3):251-5.
Whether there is an increased risk of occurrence of neuroleptic malignant syndrome (NMS) on combined treatment with lithium and neuroleptic is a controversial issue. Patients seen in a general psychiatry unit of a university hospital in India were prospectively screened for NMS over a 2 year period. Diagnosis of NMS was made on operational criteria and the details of treatment at the time of occurrence of NMS were collected systematically. Eight cases of NMS were identified during the period of the study, out of which 5 (62.5%). were taking lithium and a neuroleptic together at the time of occurrence of NMS. The high prevalence of patients on lithium and neuroleptic concomitantly in our sample of NMS, and the similar findings in many of the earlier prospective studies, makes it possible to speculate whether there is an association between combined use of lithium and neuroleptic and occurrence of NMS. Findings are discussed.
锂和神经阻滞剂联合治疗是否会增加神经阻滞剂恶性综合征（NMS）的发生风险是一个有争议的问题。在印度一家大学医院的综合精神病学病房中，我们对患者进行了为期 2 年的前瞻性 NMS 筛查。根据操作性标准诊断 NMS，并系统地收集 NMS 发生时的治疗细节。在研究期间共发现 8 例 NMS，其中 5 例（62.5%）在发生 NMS 时同时服用锂和神经阻滞剂。我们的 NMS 样本中同时服用锂和神经阻滞剂的患者比例很高，而且许多早期前瞻性研究也有类似发现，这使得我们可以推测锂和神经阻滞剂联合使用与 NMS 的发生之间是否存在关联。对研究结果进行了讨论。
Zotero 插件